The Weekly Summary

epa05066822 French President Francois Hollande (2-R), Executive Secretary of the UN Framework Convention on Climate Change (UNFCCC) Christiana Figueres (L), French Foreign Minister Laurent Fabius (C) and United Nations Secretary-General Ban Ki-moon (2-L) after the adoption of the COP21 final agreement at the plenary session room at the World Climate Change Conference 2015 (COP21) in Le Bourget, north of Paris, France, 12 December 2015. The 21st Conference of the Parties (COP21) was held in Paris from 30 November to 12 December.  EPA/CHRISTOPHE PETIT TESSON           NYTCREDIT: Christophe Petit Tesson/European Pressphoto Agency

December 7th – December 13th

In the general news, a global climate accord was reached in Paris, although it was mostly symbolic, as record warm temperatures baked the Eastern half of the country in Med-December. In the U.S., the markets sold off ahead of the Fed announcement next week.

In healthcare business news, the mega-merger between Rite Aid (RAD) and Walgreens (WBS) is drawing scrutiny from the FTC. Also, JNJ and Alphabet (GOOG) made progress on a robotic surgery platform by forming an independent company called Verb.

From the data front, Merck KGaA and Threshold’s (THLD) drug to treat solid tumors, evofosfamide, failed. Also, TherapeuticsMD’s (TXMD) drug TX-004HR, to treat vaginal pain during intercourse, succeeded.

From the FDA, Teva’s (TEVA) drug, Bendeka, to treat CLL and non-Hodgkin lymphoma was approved. Lastly, Baxalta’s (BXLT) drug, Vonvendi, to treat Von Willebrand hemophilia was approved.

This entry was posted in - The Weekly Summary. Bookmark the permalink.

Leave a Reply

Your email address will not be published.